PRTG - PORTAGE BIOTECH INC.
IEX Last Trade
4.27
-0.100 -2.342%
Share volume: 13,745
Last Updated: Mon 13 Jan 2025 10:00:00 PM CET
Research and Development in Biotechnology (except Nanobiotechnology):
-0.38%
PREVIOUS CLOSE
CHG
CHG%
$4.37
-0.10
-0.02%
Fundamental analysis
4%
Profitability
0%
Dept financing
0%
Liquidity
0%
Performance
10%
Performance
5 Days
-2.29%
1 Month
31.38%
3 Months
-42.22%
6 Months
2,272.22%
1 Year
288.18%
2 Year
-21.59%
Key data
Stock price
$4.27
DAY RANGE
$4.20 - $4.60
52 WEEK RANGE
$0.13 - $23.01
52 WEEK CHANGE
$288.18
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
N/A
Company detail
CEO: Ian B. Walters
Region: US
Website: portagebiotech.com
Employees: 6
IPO year: 2007
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: portagebiotech.com
Employees: 6
IPO year: 2007
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Portage Biotech Inc. researches and develops pharmaceutical and biotechnology products. The company's product includes IMM60, an iNKT cell activator; IMM65, a PLGA-nanoparticle combined with a NY-ESO-1 peptide vaccine; INT230-6 that is in Phase I/II clinical trials for the treatment of solid tumors; STING, a small molecule that binds to the stimulator of interferon genes in cancer; CellPorter, a cell permeable peptide platform technology.
Recent news